Incyte (INCY) Earning Somewhat Favorable News Coverage, Report Finds
Media coverage about Incyte (NASDAQ:INCY) has trended somewhat positive this week, according to Accern Sentiment. Accern identifies negative and positive media coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Incyte earned a daily sentiment score of 0.19 on Accern’s scale. Accern also assigned news articles about the biopharmaceutical company an impact score of 46.6757432244934 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
These are some of the media stories that may have effected Accern’s scoring:
- New report examines the bromodomain containing protein 2 – pipeline review, trends & SWOT analysis H1 2017 (whatech.com)
- Castleman Disease Treatment Market Trends Estimates High Demand By 2017 – 2025 (newsmaker.com.au)
- Calithera Biosciences’ (CALA) CEO Susan Molineaux on Q2 2017 Results – Earnings Call Transcript (msn.com)
- Incyte Corporation (NASDAQ:INCY) Experiences Lighter than Average Trading Volume – Modern Readers (modernreaders.com)
- Insider Trading Activity Incyte Corporation (NASDAQ:INCY) – Insider Sold 3,000 shares of Stock (4-traders.com)
Incyte (NASDAQ INCY) opened at 130.08 on Thursday. The firm’s market cap is $26.76 billion. Incyte has a 52 week low of $75.52 and a 52 week high of $153.15. The firm’s 50-day moving average price is $130.23 and its 200 day moving average price is $129.04.
Incyte (NASDAQ:INCY) last issued its quarterly earnings results on Tuesday, August 1st. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.05) by $0.01. The business had revenue of $326.40 million for the quarter, compared to the consensus estimate of $318.45 million. Incyte had a negative net margin of 3.82% and a negative return on equity of 5.03%. The business’s revenue was up 32.5% compared to the same quarter last year. During the same quarter last year, the business posted $0.18 EPS. Equities analysts forecast that Incyte will post ($0.89) earnings per share for the current fiscal year.
A number of brokerages have recently issued reports on INCY. BidaskClub cut shares of Incyte from a “buy” rating to a “hold” rating in a research report on Friday, August 4th. Barclays PLC reissued an “overweight” rating and issued a $165.00 target price (down previously from $180.00) on shares of Incyte in a research report on Wednesday, August 2nd. J P Morgan Chase & Co set a $149.00 target price on shares of Incyte and gave the company a “buy” rating in a research report on Tuesday, August 1st. Jefferies Group LLC reissued a “buy” rating and issued a $148.00 target price on shares of Incyte in a research report on Thursday, July 27th. Finally, BMO Capital Markets reissued a “buy” rating and issued a $172.00 target price on shares of Incyte in a research report on Friday, July 21st. Seven equities research analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Incyte presently has an average rating of “Buy” and an average price target of $140.39.
In related news, EVP Steven H. Stein sold 9,883 shares of the business’s stock in a transaction that occurred on Tuesday, June 20th. The stock was sold at an average price of $125.00, for a total value of $1,235,375.00. Following the completion of the sale, the executive vice president now owns 18,518 shares in the company, valued at approximately $2,314,750. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO David W. Gryska sold 16,756 shares of the business’s stock in a transaction that occurred on Monday, June 12th. The stock was sold at an average price of $116.60, for a total value of $1,953,749.60. Following the completion of the sale, the chief financial officer now owns 35,771 shares of the company’s stock, valued at approximately $4,170,898.60. The disclosure for this sale can be found here. In the last quarter, insiders have sold 48,183 shares of company stock valued at $5,976,946. Corporate insiders own 17.70% of the company’s stock.
Incyte Company Profile
Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib).
Receive News & Stock Ratings for Incyte Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte Co. and related stocks with our FREE daily email newsletter.